05 Oct Inovex Contributions toward “Bone Destiny” Osteoporosis Risk Assessment Tool Recognized @ 2012 ACR Conference in Washington, DC
Inovex’s Mike Branch is listed as a co-author alongside Dr. William Bensen and Dr. Arthur Lau for contributions toward the paper “Care Gap in the Treatment of Patients with High Risk for Fractures in a Single Canadian Academic Center”, to be presented at the 2012 American College of Rheumatology Annual Meeting November 9-14 in Washington, D.C.
In general, there is a care gap in patients who are osteoporotic based on DXA. A suboptimal percentage of patients in whom treatment is indicated are actually started on an anti-resorptive agent. A particular concern is the male population. Osteoporosis is very prevalent in males, yet diagnosis and management in males are often overlooked when compared to the female population. Bone Destiny (developed by Dr. William Bensen and operationalized by Inovex) is a validated tool which can accurately predict a patient’s 10 year fracture risk. Patients are stratified into colours (green, yellow, orange, red and purple) which range from low to high 10 year risk. Patients in the purple and red range are deemed as very high and high risk respectively, and should be treated with an anti-resorptive agent. The goal of this study was to assess if a care gap exists in the male population with a deemed as high risk by Bone Destiny.
It is important for clinicians to use a risk assessment tool to predict which patients are at high risk for fractures and start them on appropriate treatment. This study shows that a care gap indeed exists in patients at high and very high risk for fractures (red and purple on Bone Destiny). However, this gap is even more pronounced in the male population. Initiatives need to be taken in order to educate physicians and other healthcare providers about the prevalence of osteoporosis in men, and about the availability and usefulness of risk assessment tools such as Bone Destiny.